Aveva Drug Delivery Systems
United States 245 employees Updated 9 July 2026
Aveva Drug Delivery Systems is a finished-dose manufacturer based in United States. It appears in 19 regulatory filings across 2 regulators, without an active US DMF or CEP on file. Its filings concentrate with US FDA and Health Canada. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 1 September 2023 as VAI.
2
registered plants
2 with an FDA FEI number
19
filings
across 2 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
6 of 6 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 1 September 2023 VAI US FDA
- 26 July 2019 NAI US FDA
- 27 April 2018 VAI US FDA
- 11 April 2014 VAI US FDA
- 28 September 2011 VAI US FDA
- 4 December 2009 OAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| Miramar, United States | 1000307689 |
| Tamarac, United States | 3031136016 |
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| US FDA | 17 | 1 |
| Health Canada | 2 | None |
Comparing suppliers?
Choose your molecules and target markets. Aveva Drug Delivery Systems comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was VAI, on 1 September 2023.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates